The development of drug resistance is an ongoing problem in the treatment of lung cancer. New research finds that lung cancer cells can transition between drug-sensitive and drug-resistant “states.” The findings also suggest that the states can be controlled by the expression of the microRNA miR-335. Understanding how resistance arises in lung cancer is key to developing novel, more effective, treatments.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed